MedBlog

PARP-1 inhibitors can reduce ovarian cancer recurrence risk by 70% in half of patients

PARP-1 inhibitor drugs can reduce the risk of BRCA- and HRDS-associated ovarian cancer by 70%. New research at UT Southwestern Medical Center may help expand treatment to more patients.

Jayanthi Lea, M.D.

September 16, 2021